Brief: Neuren Pharmaceuticals Receives Us$100 Mln Initial Payment For Expanded Daybue™ Agreement
27/07/2023 02:33
July 27 (Reuters) - Neuren Pharmaceuticals Ltd NEU.AX :
* NEUREN RECEIVES US$100 MILLION INITIAL PAYMENT FOR
EXPANDED
DAYBUE™ AGREEMENT
Source text for Eikon: ID:nASX9YsqTx
Further company coverage: NEU.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neuren Pharmaceuticals
See all newsAustralia's Neuren set for weekly gain on FDA nod, drug forecast upgrade
Australia's Neuren Pharmaceuticals gains on upbeat FY trofinetide earnings outlook
Australia's Neuren Pharma rises as US FDA grants orphan tag for NNZ-2591
Strong partner sales propel Neuren Pharmaceuticals to top of Australia benchmark
Brief: Neuren Pharmaceuticals Says DAYBU Recommended For Approval In European Union